# Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

> **NCT02231580** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 17 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** BN82451B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02231580
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-01
- **Primary completion:** 2016-03-31
- **Final completion:** 2016-03-31
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The study was terminated due to subject recruitment problems.
- **Last updated:** 2019-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231580, "Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02231580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*